Brief: Trevi Therapeutics Completes Enrollment For Phase 2B Coral Trial
25/02/2025 14:36
Feb 25 (Reuters) - Trevi Therapeutics Inc TRVI.O: TREVI THERAPEUTICS COMPLETES ENROLLMENT FOR PHASE 2B CORAL TRIAL OF HADUVIO IN IDIOPATHIC PULMONARY FIBROSIS PATIENTS WITH CHRONIC COUGH TREVI THERAPEUTICS INC - TOPLINE RESULTS EXPECTED IN FIRST HALF OF 2025 Source text: ID:nPn2sRRb8a Further company coverage: TRVI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trevi Therapeutics
See all newsTrevi Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Trevi Therapeutics Q2 net loss widens on higher R&D costs
Brief: Trevi Therapeutics Q2 Net Income USD -17.797 Million
Trevi Therapeutics Q1 net loss widens as R&D costs rise
Brief: Trevi Therapeutics Q1 Net Income USD -13.192 Million